The Research Investments in Global Health (ResIn) study is an analysis of global investments in health research, and is based at the University of Southampton.

wordcloud diseasesOur work so far has concentrated on describing the UK portfolio of infectious disease research over the time period of 1997 to 2013. See the publications page for our numerous published outputs, and also the ‘about us’ page for our activity when informing government, funding agencies, policymakers, research institutions and individual researchers.

In 2015, we have been awarded funding from the Bill & Melinda Gates Foundation to greatly expand our work, to cover infectious disease analyses across the G20 countries, with a particular focus on the investment portfolios relate to pneumonia, neonatal infectious disease and maternal immunisation.

Tweet about this on TwitterShare on Google+Share on LinkedInShare on Facebook

Recent updates

  • First full ResIn article on cancer research investments

  • We are pleased to announce the first ResIn publication covering UK cancer research investments. It is published in BMJ Open, and the full open-access publication can be found by clicking here.

    We assessed thousands of research projects covering all types of cancer, and identify areas of research strength in the UK and areas where the portfolio is relatively weak. Breast and prostate cancers, for example, received relatively high investment compared to burden of disease whilst there was little funding for cancer of the liver, thyroid, lung, upper GI tract and bladder, despite high burdens of disease. Around two-thirds of the investment is for pre-clinical science.

     

    Tweet about this on TwitterShare on Google+Share on LinkedInShare on Facebook

  • ResIn in the news!

  • ResIn’s own Michael Head is in the UK national media today, talking about pneumonia investments. The Guardian newspaper has a supplement on antibiotic resistance, in support of the WHO’s World Antibiotic Awareness Week. See Michael on page 9 in the paper version, online link to a fuller article, or view the electronic version of the supplement (also page 9).

     

     

     

    Tweet about this on TwitterShare on Google+Share on LinkedInShare on Facebook

  • New ResIn publication – R&D funding for Ebola

  • As part of the Research Investments in Global Health study (ResIn, www.researchinvestments.org), you may be interested in this our recent paper, led by colleague Joseph Fitchett and with Rifat Atun as senior author – we described funding for ebola R&D in the years prior to the 2014 outbreak and the responsive funding during the first year of the outbreak, covering $1 billion of investments from US and UK government, Wellcome, Gates etc. We’ve charted the funder, destination of those funds, and what they’re for (e.g. vaccine, diagnostics, therapeutics).

    Now published ‘online first’ at Journal of Global Health

    Paper is here – http://www.jogh.org/documents/issue201602/jogh-06-020703.XML

    PDF is here – http://www.jogh.org/documents/issue201602/jogh-06-020703.pdf

    Tweet about this on TwitterShare on Google+Share on LinkedInShare on Facebook